Metropolis Healthcare has completed the acquisition of Core Diagnostics from Core Diagnostics (Mauritius). The company’s board has approved the allotment of equity shares of the company on a preferential basis to Core Diagnostics (Mauritius) as part of the agreed purchase consideration, while the remaining balance of the purchase consideration has been remitted in cash to Core Diagnostics (Mauritius), with Rs 5 crore withheld as deferred consideration to be paid subject to closing adjustments by the parties. Core Diagnostics (Mauritius) has transferred its 100% stake in Core Diagnostics to the company, and necessary confirmations have been received from the respective Depository Participants as part of this process. With this, Core Diagnostics becomes a wholly owned subsidiary of the company.
Earlier, the company’s board had approved the acquisition of the 100% stake in Core Diagnostics from Core Diagnostics (Mauritius). This strategic acquisition will enhance company’s advanced cancer testing capabilities and strengthen its footprint in Northern and Eastern India. By leveraging Core Diagnostics’ strong relationships with leading cancer specialists and hospitals in these regions, the company aims to expand its market reach and specialized testing offerings. The acquisition also provides an opportunity to offer Metropolis’ broad range of diagnostic services to Core Diagnostics’ network, while bringing Core Diagnostics’ advanced cancer testing to its existing customer base. Moreover, the integration is expected to drive synergies through optimized laboratory operations, improved efficiencies, and cost reductions, further solidifying Metropolis’ leadership in the diagnostics industry.
Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services.
| Company Name | CMP |
|---|---|
| Apollo Hospital Ent. | 6472.75 |
| Max Healthcare Inst | 1131.00 |
| Narayana Hrudayalay | 1675.65 |
| Aster DM Healthcare | 435.35 |
| Global Health | 1224.65 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
100% Secure Process
Account Discovery
- OTP from CAMS
Account Linking for Stocks & MF
- One OTP per link Eg. NSDL, CDSL, CAMS, KFin etc.
One Click Upload for your Current Portfolio and Future Transactions!
Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
